Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
about
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationNovel vaccination approaches to prevent tuberculosis in childrenA Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness Cost That Is Modified by TCR Affinity during TuberculosisNovel adjuvant formulations for delivery of anti-tuberculosis vaccine candidatesCurrent status of new tuberculosis vaccine in children.A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Towards new TB vaccines: What are the challenges?Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.Vaccine adjuvants: Why and how.Adjuvant system AS01: helping to overcome the challenges of modern vaccines.Polyfunctional CD4+ T Cells As Targets for Tuberculosis VaccinationMultiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?The current status, challenges, and future developments of new tuberculosis vaccines.Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent TuberculosisThe TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
P2860
Q28074536-2D2D8636-197E-4A73-BDFA-FF7AE0DD096FQ33801426-609EC052-B726-487E-9AFC-B4D2413D6D89Q35888761-F4FE5AF7-C8EC-4EBE-BF62-4F72582DC881Q36909492-F4427B3C-8271-4B64-9287-A9D7202C5BDAQ37130796-28C6147C-EF19-4CA2-9D59-F1542143B19DQ37204894-7BA49EF4-66EA-4183-A6D0-C39CA90BC738Q37587612-9C550076-E6A0-4152-8EC9-FE0C9D25673AQ38724073-225E66DD-D752-43E4-8F1D-1BE2F2AEAA8FQ38767468-54DDEDFA-5EBB-4B95-B674-B6F9D9C1BB13Q39604583-6A1E8170-74A0-45E4-A2EC-CD86B2D783CCQ39748955-CE94F935-3795-4FB6-B56C-9C7AC6E7238EQ40064119-AF2FFC88-ABD4-4A9F-8C36-8C1317DD4AECQ40566411-79F88850-044B-4CA8-80E2-5EF35514BD6CQ42051427-19C501F9-4601-4A77-93B2-BD341B44FCD2Q42373425-B73CB8F8-F327-4FCB-B5BA-529400BD169FQ42692800-FFCE42D1-3C0D-4FF2-9761-D0DEC5F8705DQ52337140-D62BFFCE-3B88-4FDF-9FC4-F512C8AF1D2FQ52597636-A60862B0-B19B-4A65-B527-0F0BED71D733Q57069957-847F2881-D400-4B9C-930A-ECBD96307269Q58765317-547B0730-86A8-45AD-9A94-288DAB1C7AAB
P2860
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety and immunogenicity of c ...... cents in a TB endemic setting.
@en
type
label
Safety and immunogenicity of c ...... cents in a TB endemic setting.
@en
prefLabel
Safety and immunogenicity of c ...... cents in a TB endemic setting.
@en
P2093
P2860
P50
P1433
P1476
Safety and immunogenicity of c ...... cents in a TB endemic setting.
@en
P2093
Adam Penn-Nicholson
Angelique Kany Kany Luabeya
Anne Bollaerts
Cheryl L Day
Didier Lapierre
Erik Jongert
Evi De Ruymaeker
Hennie Geldenhuys
Marie-Ange Demoitie
Michele Tameris
P2860
P304
P356
10.1016/J.VACCINE.2015.05.088
P407
P577
2015-06-10T00:00:00Z